Skip to main content

Iron Overload

8
Pipeline Programs
6
Companies
10
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
7
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Chiesi
FERRIPROXApproved
deferiprone
Chiesi
Iron Chelator [EPC]oral2020
4M Part D

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
7 programs
1
4
DeferasiroxPhase 41 trial
DeferasiroxPhase 41 trial
DesferasiroxPhase 41 trial
deferasiroxPhase 41 trial
DeferasiroxPhase 1/21 trial
+2 more programs
Active Trials
NCT01034072Completed75Est. Jan 2012
NCT00395629Completed49Est. Mar 2009
NCT00654589Completed75Est. Jan 2012
+3 more trials
Chiesi
ChiesiBrazil - Santana de Parnaíba
2 programs
2
DeferipronePhase 41 trial
DeferipronePhase 41 trial
Active Trials
NCT02443545Terminated134Est. Aug 2019
NCT02041299Terminated230Est. Jun 2019
Novartis
NovartisBASEL, Switzerland
2 programs
Iron Overload in Pediatric Oncology PatientsN/A
DesferasiroxPHASE_4
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Changes in Pituitary Iron and Volume With DeferasiroxN/A1 trial
Active Trials
NCT01376622Completed130Est. Jul 2011
One Biosciences
One BiosciencesFrance - Paris
1 program
R2*-UTEN/A1 trial
Active Trials
NCT01572922CompletedEst. Feb 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozDeferasirox
ChiesiDeferiprone
ChiesiDeferiprone
SandozDesferasirox
Sandozdeferasirox
SandozDeferasirox
SandozDeferasirox
One BiosciencesR2*-UTE
SandozIron Overload in Pediatric Oncology Patients
Angeles TherapeuticsChanges in Pituitary Iron and Volume With Deferasirox

Clinical Trials (10)

Total enrollment: 831 patients across 10 trials

NCT03372083SandozDeferasirox

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Start: Jan 2018Est. completion: Dec 201944 patients
Phase 4Completed
NCT02443545ChiesiDeferiprone

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Start: May 2015Est. completion: Aug 2019134 patients
Phase 4Terminated
NCT02041299ChiesiDeferiprone

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Start: Apr 2014Est. completion: Jun 2019230 patients
Phase 4Terminated
NCT01546415SandozDesferasirox

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Start: Oct 2011Est. completion: Nov 201364 patients
Phase 4Completed
NCT01335035Sandozdeferasirox

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Start: Dec 200830 patients
Phase 4Completed
NCT00654589SandozDeferasirox

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Start: Feb 2008Est. completion: Jan 201275 patients
Phase 4Completed
NCT00395629SandozDeferasirox

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Start: Aug 2006Est. completion: Mar 200949 patients
Phase 1/2Completed
NCT01572922One BiosciencesR2*-UTE

Massive Iron Deposit Assessment

Start: Jun 2012Est. completion: Feb 2018
N/ACompleted
NCT01034072SandozIron Overload in Pediatric Oncology Patients

Iron Overload in Pediatric Oncology Patients

Start: Dec 2009Est. completion: Jan 201275 patients
N/ACompleted
NCT01376622Angeles TherapeuticsChanges in Pituitary Iron and Volume With Deferasirox

Changes in Pituitary Iron and Volume With Deferasirox

Start: Nov 2008Est. completion: Jul 2011130 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.